Flu vaccine selection
Vaccines & Related Biological Products Advisory Committee postpones until mid-March selection of influenza A H3N2 vaccine strain for 2003-2004 flu season pending further analysis of new virus strains. Current vaccine strain, A/Panama/2007/99, has been ineffective at inhibiting recent strains marked by altered amino acid sequence, FDA and CDC reps said during Feb. 20 meeting. FDA committee is expected to hold teleconference March 17 or 18 on strain selection, at which time the panel also could hear data about occurrence of avian influenza virus (A H5N1) in Hong Kong. Committee voted to retain current A H1N1 (New Caledonia/20/99) and B (Hong Kong/330/2001 and 1434/02) strains...
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.